Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

Roche shares new data showing its MS drug fenebrutinib maintained low relapse rates and no disability progression in patients ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has ...

Objective To establish a rigorous, expert-led, evidence-based approach to the evaluation of licensed drugs for repurposing and testing in clinical trials of people with progressive multiple sclerosis ...

New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of ...

A common sleep aid restores healthier sleep patterns and protects mice from the brain damage seen in neurodegenerative ...